Actively Recruiting
A Study of C-CAR039 (Prizloncabtagene Autoleucel) in Patients With Relapsed/Refractory Large B-Cell Lymphoma
Led by Shanghai AbelZeta Ltd. · Updated on 2025-12-31
112
Participants Needed
15
Research Sites
279 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a multicenter, single arm, open-label study. The purpose of the study is to evaluate safety of Prizloncabtagene Autoleucel (Prizlon-cel) and establish the recommended Phase 2 dose (RP2D) (Phase 1b) and to evaluate the efficacy of Prizlon-cel (Phase 2) in patients with relapsed or refractory large b-cell lymphoma (LBCL).
CONDITIONS
Official Title
A Study of C-CAR039 (Prizloncabtagene Autoleucel) in Patients With Relapsed/Refractory Large B-Cell Lymphoma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- 18 years of age or older
- Histologically confirmed CD19 or CD20 positive B-cell non-Hodgkin lymphoma, including diffuse large B-cell lymphoma, primary mediastinal large B-cell lymphoma, transformed follicular lymphoma, high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements, high-grade B-cell lymphoma not otherwise specified, or follicular lymphoma grade 3B
- Relapsed or refractory disease after two or more lines of standard therapy or relapse after autologous stem cell transplantation
- At least one measurable lesion according to the Lugano 2014 Classification
- Adequate organ and bone marrow function
You will not qualify if you...
- Prior allogeneic hematopoietic stem cell transplantation at any time or autologous stem cell transplantation within 12 weeks prior to apheresis
- Suspected or confirmed central nervous system involvement
- History of stroke or convulsions within 6 months before signing the informed consent
- Autoimmune disease, immunodeficiency, or diseases requiring immunosuppressant treatment
- Uncontrolled active infection
- Positive hepatitis B surface antigen or hepatitis B core antibody with detectable hepatitis B virus DNA
- Positive hepatitis C virus antibody with detectable hepatitis C virus RNA
- Positive human immunodeficiency virus antibody
- Positive syphilis test
- Severe heart, liver, kidney, or metabolic disease
- Inadequate washout time from previous anti-tumor treatments before apheresis
- Previous treatment with CAR-T therapy
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 15 locations
1
Beijing Cancer Hospital
Beijing, China
Completed
2
Beijing GoBroad Hospital
Beijing, China
Actively Recruiting
3
Peking University Third Hospital
Beijing, China
Actively Recruiting
4
Chongqing University Cancer Hospital
Chongqing, China
Actively Recruiting
5
Guangdong Provincial People's Hospital
Guangzhou, China
Actively Recruiting
6
Zhujiang Hospital of Southern Medical University
Guangzhou, China
Actively Recruiting
7
The First Affiliated Hospital Zhejiang University School of Medicine
Hangzhou, China
Actively Recruiting
8
Cancer Hospital of Shandong First Medical University
Jinan, China
Actively Recruiting
9
Jiangxi Cancer Hospital
Nanchang, China
Actively Recruiting
10
Jiangsu Province Hospital
Nanjing, China
Actively Recruiting
11
Ruijin Hospital, Shanghai Jiaotong University School of Medicine
Shanghai, China
Actively Recruiting
12
Chinese Academy of Medical Sciences Hematology Hospital
Tianjin, China
Actively Recruiting
13
Tianjin Medical University Cancer Institute& Hospital
Tianjin, China
Actively Recruiting
14
Henan Cancer Hospital
Zhengzhou, China
Actively Recruiting
15
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, China
Actively Recruiting
Research Team
W
Weili Zhao, M.D., PhD
CONTACT
L
Lugui Qiu, M.D., PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here